anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is a dose-finding study of N-acetylcysteine (NAC) to protect hearing in children receiving cisplatin for the treatment of their cancer. NAC also has potential to protect the kidneys from cisplatin toxicity.

The study uses a 3+3 dose-escalation scheme to determine the dose of NAC necessary to achieve serum levels consistent with hearing protection in pre-clinical animal models. Three dose levels are predefined. Once the maximum tolerated dose is determined, an expansion cohort will then be enrolled to further evaluate tolerability as well as intra-patient and inter-patient variability in achieved serum levels. An option to enroll in a separate arm for study assessments only is available for those who do not wish to receive NAC. Hearing loss in the cohort will be assessed in the entire cohort in comparison to historical and non-treated children to evaluate for trends toward efficacy.
Stable pharmaceutical compositions containing a salt of an ester of choline or a homologue thereof are prepared by dissolving a non-toxic salt of said ester in a parentally acceptable, water-miscible organic solvent and adjusting the pH of the resulting solution to 2.8 to 3.5 by adding to the solution a physiologically acceptable organic or inorganic acid or an acidic ion exchange resin.  Suitable salts are derived from bis-esters of choline or its homologues with dibasic acids, e.g. malonic, succinic, glutaric, adipic, pimelic, maleic and fumaric acids.  The anions of the salts may be derived from acids such as, sulphuric, nitric, phosphoric, hydriodic, hydrobromic, hydrochloric, citric, acetic and tartaric acids.  Solvents specified are ethanol, propylene glycol, glycerine, glycerine formal, N, N-dimethylacetamide, dimethyl sulphoxide and dioxane. Acidifying agents mentioned are nitric, phosphoric, hydrochloric, fumaric, adipic, succinic and citric acids, and Dowex 50 W and Amberlite IRC-50 ion exchange resins ("Dowex" and "Amberlite" are Registered Trade Marks).
Patients in the control group receive 6 sessions of Motor Imagery + FES + VR therapy per week for 4 weeks (24 sessions in total). Patient in the control group will receive the same instructions as the experimental group.
An adjustable storage rack for use with parts of a variety of shapes and sizes. An adjustable storage rack of the present invention allows for easy horizontal and/or vertical repositioning of the points of part support, thus rendering such a cart useable with dissimilar parts. Various part support structures may also be used, thereby further increasing the flexibility of a rack of the present invention. A part support structure of the present invention may be equipped with a latching mechanism that secures its vertical position. A storage rack of the present invention can be provided with wheels or other means for facilitating transport thereof. As such, a storage rack of the present invention can be used to transport, as well as store, parts.
In formula (I), R1 and R4 each independently represent a hydrogen atom, or an unsubstituted or substituted C1 to C6 alkyl group or the like. R2 represents a hydrogen atom, or an unsubstituted or substituted C1 to C6 alkyl group or the like. R3 represents an unsubstituted or substituted C1 to C6 alkyl group or the like. R5 represents a C1 to C6 haloalkyl group or the like. G represents an oxygen atom or a sulfur atom. R6 and R7 each independently represent a hydrogen atom, or an unsubstituted or substituted C1 to C6 alkyl group or the like. n represents 0 or 1. R8 and R9 each independently represent a hydrogen atom, or an unsubstituted or substituted C1 to C6 alkyl group. Ar represents an unsubstituted or substituted C6 to C10 aryl group or the like.
FIELD: biotechnology, microbiology. SUBSTANCE: protein exhibiting pore-forming function in cellular wall of meliodosis pathogen and purified from cytoplasmic proteins and peptidoglycan is administrated to meliodosis-sensitive animal by subcutaneous route at dose 880-7000 mcg/mg animal mass. Immunization is carried out by schedule that is experimentally adopted to each animal species. Protective effect estimation is carried out by subcutaneous infection of animals with virulent culture of meliodosis microorganism. Method provides survival 100% white rats infected with subcutaneous dose ID 50  of agar culture of high-virulent strain of Pseudomonas pseudomallei CN-141. EFFECT: improved method of prophylaxis. 2 tbl
The cornerstone of obesity treatment is behavioural weight management, resulting in significant improvements in cardio-metabolic and psychosocial health. However, there is ongoing concern that dietary interventions used for weight management may precipitate the development of eating disorders. Systematic reviews demonstrate that, while for most participants medically supervised obesity treatment improves risk scores related to eating disorders, a subset of people who undergo obesity treatment may have poor outcomes for eating disorders. This review summarises the background and rationale for the formation of the Eating Disorders In weight-related Therapy (EDIT) Collaboration. The EDIT Collaboration will explore the complex risk factor interactions that precede changes to eating disorder risk following weight management. In this review, we also outline the programme of work and design of studies for the EDIT Collaboration, including expected knowledge gains. The EDIT studies explore risk factors and the interactions between them using individual-level data from international weight management trials. Combining all available data on eating disorder risk from weight management trials will allow sufficient sample size to interrogate our hypothesis: that individuals undertaking weight management interventions will vary in their eating disorder risk profile, on the basis of personal characteristics and intervention strategies available to them. The collaboration includes the integration of health consumers in project development and translation. An important knowledge gain from this project is a comprehensive understanding of the impact of weight management interventions on eating disorder risk.
The slow released antituberculotic preparation contains the composition of ofloxacin, ciprofloxacin or sparxacin, capreomycin, sodium taurocholate and/or deoxysodium taurocholate. The slow released antituberculotic preparation is slow released injection or slow released implanting agent. The injection consists of slow released microsphere and solvent. The slow released microsphere contains slow releasing supplementary material and antituberculotic and the solvent is special solvent containing suspending agent carboxymethyl cellulose, etc. and with viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from EVAc, PLA, PLGA, etc. The slow released implanting agent is prepared through a certain process. The present invention has obvious unique treating effect on various kinds of intractable tuberulosis.
Otrexup is an auto-injector intended for subcutaneous use under the guidance and supervision of a physician.

Patients may self-inject with Otrexup if a physician determines that it is appropriate, if they have received proper training in how to prepare and administer the correct dose, and if they receive medical follow-up, as necessary. A trainer device is available for training purposes.

Visually inspect Otrexup for particulate matter and discoloration prior to administration. Do not use Otrexup if the seal is broken.

Handle and dispose of Otrexup consistent with recommendations for handling and disposal of cytotoxic drugs1.
Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically expressed by CSCs are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of cancer, and more particularly cancers associated with the presence of CSCs such as poorly differentiated cancers, is also described.
Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years). Qualified participants who receive first course of pembrolizumab but continue to experience disease progression may, at investigator's discretion, initiate a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to \~1 year).
Subjects with advanced or metastatic solid tumor will receive Mitoxantrone Hydrochloride Liposome every 28 days (a cycle) for a maximum of 8 cycles. The starting dose of Mitoxantrone Hydrochloride Liposome is 20mg/m2.
Dystonia affecting athletes has received little research attention and there has been a lack of awareness or interest among both physicians and athletes. Task-specific dystonias or occupational cramps affect people while writing, typing, and or playing a musical instrument. Our group has previously shown that a subset of golfers who complain of the yips appear to have a task-specific dystonia or golfer's cramp. The yips are characterized by an inability to appropriately complete a golf stroke, most often putting and chipping strokes. Most individuals with the yips describe a jerking or shaking movement that interrupts their swing. In many cases the yips are disabling and the golfer, including professional tour players, give up golfing.

Golfers who have evidence of golfer's cramp will putt a series of putts during which they will be monitored for arm movements and putter movements. They will then be treated with a low dose of propranolol to see if there is a change in these parameters.
Clinical, randomized and controlled trial, conducted in a pediatric surgery ward of a university hospital in São Paulo. Data collection occurred from February 26th, 2007 to July 07th, 2008, after ethical merits of research approval. The sample comprised 382 venous puncture randomly allocated in the experimental group (EG), venous puncture guided by VUS, or in the control group (CG), traditional method of venous puncture. Variables related to children, intravenous therapy and professional characterization were collected. The dependent variables included the obtainment of peripheral venous access, the assertiveness, the catheter dwell time and the occurrence of local complications. For the statistical analysis were applied the Pearson Chi-square, Fisher's Exact, Generalization of Fisher's exact, Mann-Whitney, Likelihood Ratio and Prevalence Ratio (significance level of 5%).
Sepsis is a major cause of death worldwide, with a mortality rate that has remained stubbornly high. The current gold standard of risk stratifying sepsis patients provides limited mechanistic insight for therapeutic targeting. An improved ability to predict sepsis mortality and to understand the risk factors would allow better treatment targeting. Sepsis causes metabolic dysregulation in patients; therefore, metabolomics offers a promising tool to study sepsis. It is also known that that in sepsis endothelial cells affecting their function regarding blood clotting and vascular permeability. We integrated metabolomics data from patients admitted to an intensive care unit for sepsis, with commonly collected clinical features of their cases and two measures of endothelial function relevant to blood vessel function, platelet endothelial cell adhesion molecule and soluble thrombomodulin concentrations in plasma. We used least absolute shrinkage and selection operator penalized regression, and pathway enrichment analysis to identify features most able to predict 30-day survival. The features important to sepsis survival include carnitines, and amino acids. Endothelial proteins in plasma also predict 30-day mortality and the levels of these proteins also correlate with a somewhat overlapping set of metabolites. Overall metabolic dysregulation, particularly in endothelial cells, may be a contributory factor to sepsis response. By exploring sepsis metabolomics data in conjunction with clinical features and endothelial proteins we have gained a better understanding of sepsis risk factors.
1403387 Mixed solubility (meth)acrylate polymers CESKOSLOVENSKA AKADEMIE VED 11 Oct 1972 [14 Oct 1971] 46788/72 Heading C3P A mixture of soluble and insoluble crosslinked hydrophilic (meth)acrylate polymers is prepared by dissolving in an inert solvent (a) a polyhydric alcohol monomethacrylate and/or monoacrylate in an amount not more than 34% by weight of the total polymerization solution and (b) from 0À005 to 0À2% by volume, based on the total polymerization solution, of a corresponding poly-(meth)acrylate; effecting free radical precipitation polymerization of the solution obtained; and separating out, in the form of discrete particles, the resultant mixture of soluble and insoluble cross-linked polymer products, the inert solvent being such that the polymer products are neither substantially swelled nor substantially dissolved thereby. (The terms "soluble" and "insoluble" are defined as meaning that a polymer is soluble or insoluble, respectively, in at least methanol.) The polymerization solution may also include other comonomers but the use of 5-95%, based on the total weight of monomers employed, of nbutyl acrylate or methacrylate is disclaimed. Suitable solvents for the process include aromatic hydrocarboris optionally partially hydrogenated, halogenated hydrocarbons, carboxylic acid esters of aliphatic alcohols, (cyclo) ethers and (cyclo)-ketones; the solvent may further include a proportion of an aliphatic or cycloaliphatic hydrocarbon. Polymerization is initiated with a conventional compound such as benzoyl peroxide, t-butyl peroctoate, diisopropyl percarbonate, cumene hydroperoxide or azobisisobutyronitrile. Polymerization may be effected continuously or batchwise, preferably with the monomers being added at a rate dependent upon the precipitation rate of the polymer. The polymer products are useful as reinforcing agents for hydrophilic polymer gels, one particular application being in soft hydrophilic gel layers for hard acrylic dentures.
Adolescent depression is a significant public health problem, and it increases the risk of poor psychosocial outcomes in adolescence and adulthood. Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) has been found to be an effective treatment for reducing adolescents' depressive symptoms and improving their global and social functioning. The purpose of the current study is to examine the feasibility and acceptability of IPT-A when it is delivered with greater and more structured involvement of the parents in the treatment.

Participants will receive 15 weeks of Interpersonal Psychotherapy for Depressed Adolescents and Parents (IPT-AP). Eight the therapy sessions are conducted with the adolescent individually, two are with the parent(s) individually, and five are conducted with the adolescent and parent(s) together. At the end of the 15 weeks, participants who have demonstrated at least a 50% reduction in depressive symptoms will participate in three booster sessions delivered on a monthly basis. All participants will be assessed at baseline, week 5, week 10, week 15 (post-treatment), and 3 months post-treatment to measure depressive symptoms, global and social functioning, and attitudes toward treatment.
The participants in this group were started to watch videos by wearing virtual reality glasses about 2 minutes before the catheterization process was started and the process was continued until the end. Then, catheterization was performed by detecting the tourniquet by the emergency department nurse. Upon completion of the catheterization procedure, VRG was removed from the procedure area by the researcher. This process took an average of 5 minutes. After the procedure was completed, the pain and satisfaction status of the patients were scored on the VAS by the same nurse.
The kappa opioid receptor (KOR) and its endogenous agonist dynorphin have been implicated in multiple psychiatric conditions including psychotic disorders. We tested the hypotheses that kappa expression is elevated and associated with psychotic symptoms in schizophrenia. We measured kappa expression in unmedicated patients with schizophrenia (7 female, 6 male) and matched controls (7 female, 6 male) with positron emission tomography (PET). We also acquired a measurement of cumulative dopamine activity over the life span in the same subjects using neuromelanin sensitive MRI. We hypothesized that neuromelanin accumulation would be higher in patients than controls and that in patients there would be a positive association between KOR availability and neuromelanin accumulation. Fourteen patients and thirteen controls were enrolled. Whole brain dynamic PET imaging data using the KOR selective tracer [18F]LY245998 were acquired. Distribution volume (VT) was measured with region of interest analysis in 14 brain regions. Neuromelanin accumulation in midbrain dopaminergic nuclei was assessed in the same subjects. Positive and negative symptoms were measured by a clinical psychologist. We did not observe group level differences in KOR expression, neuromelanin accumulation or relationships of these to positive symptoms. Unexpectedly, we did observe strong positive associations between KOR expression and symptoms of anhedonia in the patients (Pearson r > 0.7, uncorrected p < 0.01 in 8 cortical brain regions). We also observed moderate associations between KOR expression and neuromelanin levels in patients. In conclusion, we did not observe a relationship between kappa and symptoms of psychosis but the observed relationship to the negative symptom of anhedonia is in line with recent work testing kappa antagonism as a therapy for anhedonia in depression.
PURPOSE:To provide a monoclonal antibody recognizing the alpha-fetoprotein existing at the surface of cell membrane, and useful for the remedy of hepatocarcinoma, especially as an antibody for missile therapy. CONSTITUTION:A monoclonal antibody recognizing the alpha-fetoprotein (AFP) exsisting at the surface of cell membrane. In the markers of carcinoma, AFP and fetus antigen (CEA) are well known, and AFP is produced in various hepatocarcinoma and cerulein. Since said monoclonal antibody recognizes the AFP existing at the surface of cell membrane, it is suitable for the missile therapy by bonding the antibody with a carcinostatic agent or a toxin. The antibody can be prepared by (1) immunizing e.g. BALB/C mouse with AFP originated from human placenta, (2) extracting the spleen from the immunized animal, (3) carrying out the fusion with the mouse myeloma cell of e.g. P3-U1 using polyethylene glycol by conventional method to obtain a hybridoma, and (4) separating from the supernatant liquid. The monoclonal antibody prepared by this process is effective to dye the hepatocarcinoma cerulein immunochemically, and to select the positive antibody.
One or more preferred embodiments facilitate use of patient panomics indications to select treatments that will provide optimal results. One or more preferred embodiments relate to a practical ontology for the panomics domain that is utilized to support use of patient panomics indications. In accordance with one or more preferred implementations, a cancer panomics ontology facilitates replacement of traditional cancer stratification by organs (e.g. lung, breast, liver cancer) with cancer stratification by tumor biomarkers (e.g. HER2 mutations). In accordance with one or more preferred implementations, a panomic ontology is utilized to facilitate functionality of a precision medical system.
Participants in the CAU group will complete baseline questionnaires and be informed that they will receive access to Powerly six weeks postpartum. They will be invited to complete the questionnaires again 28 days later, and once more six weeks postpartum.
In this phase 2 study, a single dose of AV-COVID-19 DCL vaccine is injected subcutaneously in the forearm (left or right) at week 0 (day-0), to facilitate inspection and avoid confusion of local post-injection reactions or shoulder pain. Follow-up visits to assess safety are performed at 1, 2, and 4 weeks after vaccination, with laboratory safety tests performed at weeks 1 and 4, and only at week 2 if any clinically significant changes at screening up to week 1. At each visit, the injection site is assessed, and the subject is asked about symptoms, and at weeks 0 (baseline before injection), 2 and 4, blood is drawn for immunogenicity testing. Reaction data at the injection site and safety profile are obtained by telephone to subjects on days 1, 2, and 3 after vaccine injection. Subjects are asked specifically about local injection site reactions and systemic flu-like symptoms (fever, chills, muscle aches, joint pain) for 7 days after injection. Adverse events (AE) are collected for 28 days after injection. Evaluation of laboratory tests for clinical safety parameters are carried out at screening as well as immediately before vaccination and on day 7 and day 28 post-vaccination. Serious adverse events (SAE), recent medical conditions, and other events requiring medical intervention are recorded for 2 months after vaccination. Vaccine enabling kits are made by PT AIVITA Biomedika Indonesia. All vaccines are made in Indonesia on site at participating hospitals and clinical sites.
A composition for hair, which contains branched fatty acid as a main ingredient is provided to supplement denaturation and loss of hair by physical damage or chemical damage. A composition for hair comprises 0.001-20 weight part of branched chain fatty acid or its mixture based on total hair composition. The branched chain fatty acid comprises 18-methyl eicosane (18-MEA), 16-methyl octadecanoic acid, and 14-methyl heptadecanoic acid (14-MHA). The branched fatty acid mixture is a human or animal derived fatty acid mixture. The branched chain fatty acid is a compound of the chemical formula I. In the chemical formula I, n is 2-11 and m is 1. The composition is applied to the liquid phase, cream phase, emulsion or solid phase and is used in a form of shampoo, rinse, treatment, essence, ample, tonic and soap.
PURPOSE:To call a fuzzy database being applicable with a product name by converting the fuzzy database to the database combined with a color material and the product name. CONSTITUTION:A knowledge database 2 is generated by combining a color material catalog to a fuzzy database 1. A product name database 4 is generated by combining a product name to this knowledge database 2. By an environment setting module 6, use conditions of a spectrophotometer for measuring a color tone of an external appearance color and an applying color and a type of an applying robot, etc., are set. Also, data of the external appearance color and the applying color of a standard color is recorded in ST files 6, 7. Subsequently, color tone data obtained by measuring the actual external appearance color and applying color is recorded in the respective measuring modules 9, 10 through a communication control module 8, a fuzzy inference is execute, based on the fuzzy data base by a synthetic decision module 11, and the data is inputted to color tone data 12, and also, outputted to a graph 13 and a printer 14.